9/29/2016. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? Current state of liver transplantation (LT) for HCC
|
|
- Kathryn Patrick
- 7 years ago
- Views:
Transcription
1 UCSF Transplant 2016: Building Bridges to Excellence OVERVIEW Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? Neil Mehta, MD 9/29/16 UCSF Division of Gastroenterology and Hepatology Current state of liver transplantation (LT) for HCC Let s push past the Milan criteria Refining selection criteria for LT Updates in down-staging outcomes Proposed UNOS policy changes Risk factors for post-lt HCC recurrence How often to perform surveillance? LIVER TRANSPLANTATION FOR HCC MILAN CRITERIA LIVER TRANSPLANTATION FOR HCC T1 and T2 CRITERIA 1 lesion 5 cm 2 to 3, none > 3 cm T1: 1 lesion < 2 cm T2: 1 lesion 2-5 cm or 2 to 3 lesions, none >3cm + Absence of Macroscopic Vascular Invasion Absence of Extra-hepatic Spread + Absence of Macroscopic Vascular Invasion Absence of Extra-hepatic Spread Mazzaferro, et al. N Engl J Med 1996;334:
2 of adult LT done for HCC RISING INCIDENCE OF LT FOR HCC UCSF DATA LT for HCC in of adult LT done for HCC RISING INCIDENCE OF LT FOR HCC UCSF DATA LT for HCC in LT for HCC in Year Year LIVER TRANSPLANT FOR HCC: PROBLEMS & CHALLENGES HCC misdiagnosis Outcome after liver transplant for HCC still slightly worse than that for non-hcc indications 1 HCC patients receiving unfair advantage for donors compared to non-hcc patients 2,3 1. Ioannou GN, et al. Gastroenterology 2008; 134: Washburn K, et al. Am J Transpl 2010;10: Goldberg D, et al. Liver Transpl 2012;18: OUTCOME OF LIVER TRANSPLANT FOR HCC IN THE MELD ERA ( ) N Adjusted * Patient Survival () HR (95 CI) 1 yr 2 yr 3 yr 4 yr No HCC HCC, no exception ( ) HCC, MELD ( ) exception HCC, MELD ( ) exception (> 2 cm) *Adjusted for MELD score, underlying liver disease, age, gender, race/ethnicity, BMI and donor age (+ other donor factors) Ioannou GN, et al. Gastroenterology 2008; 134:
3 WAITLIST DROPOUT OR DEATH: HCC VS NON-HCC 25 Too sick Died 20 P< P< P< LIVER TRANSPLANT FOR HCC: RECENT CHANGES Uniform diagnostic criteria (OPTN/ LIRADS) + standardized reporting Only pts w/ T2 HCC and LI-RADS 5 lesions are eligible to receive priority listing 5 0 HCC Non-HCC MELD 22 MELD HCC Non-HCC MELD 25 MELD HCC Non-HCC MELD 28 MELD Goldberg D, et al. Liver Transpl 2012;18: LIVER TRANSPLANT FOR HCC: RECENT CHANGES Uniform diagnostic criteria (OPTN/ LIRADS) + standardized reporting Only pts w/ T2 HCC and LI-RADS 5 lesions are eligible to receive priority listing LI-RADS 5: Definite HCC LI-RADS 4: Probable HCC LI-RADS 3: Indeterminate LIVER IMAGING REPORTING AND DATA SYSTEM (LI-RADS) Diagnostic Criteria Arterial phase hypo- or Isoenhancement LIVER MASS Arterial phase hyperenhancement < 2 cm 2 cm < 1 cm cm 2 cm Washout None LIRADS 3 LIRADS 3 LIRADS 3 LIRADS 3 LIRADS 4 Capsule One LIRADS 3 LIRADS 4 LIRADS 4 LIRADS 4 LIRADS 5 Threshold growth Two LIRADS 4 LIRADS 4 LIRADs 4 LIRADS 5 LIRADS 5 3
4 LIVER IMAGING REPORTING AND DATA SYSTEM (LI-RADS) Diagnostic Criteria Arterial phase hypo- or Isoenhancement LIVER MASS Arterial phase hyperenhancement < 2 cm 2 cm < 1 cm cm 2 cm Washout None LIRADS 3 LIRADS 3 LIRADS 3 LIRADS 3 LIRADS 4 Capsule One LIRADS 3 LIRADS 4 LIRADS 4 LIRADS 4 LIRADS 5 Threshold growth Two LIRADS 4 LIRADS 4 LIRADs 4 LIRADS 5 LIRADS 5 LIVER TRANSPLANT FOR HCC: RECENT CHANGES Uniform diagnostic criteria (OPTN/ LIRADS) + standardized reporting 6-month mandatory waiting period before MELD exception of 28 Cap at MELD of 34 DELAYED HCC-MELD EXCEPTION SCORE Delays in HCC-MELD exception HCC Transplant rates (per 100 person-years) Non-HCC Transplant rates (per 100 person-years) months Do poorly after transplant 6 months months Moving past one-size fits all Heimbach J, et al. Hepatology 2015;61: Mehta N, and Yao FY. Liver Transpl 2013;19:
5 - Local regional therapy - Observation period/ Wait time - Local regional therapy - Observation period/ Wait time Do poorly after transplant Do poorly after transplant Tumor Down-staging Do poorly after transplant 20 Do poorly after transplant (or less urgent) 5
6 SUBGROUP WITH LOW DROPOUT RISK Criteria for low dropout risk 1 lesion 2-3 cm Complete response to 1 st treatment AFP after 1 st treatment < 20 ng/ml SUBGROUP WITH LOW DROPOUT RISK Criteria for low dropout risk 1 lesion 2-3 cm Complete response to 1 st treatment AFPafter1 st treatment < 20 ng/ml Cumulative dropout risks of 1.3 at 1 year, and 1.6 at 2 years. Accounts for 20 of entire cohort Mehta N, et al. Liver Transpl 2013;19: Mehta N, et al. Liver Transpl 2013;19: PROPOSED UNOS POLICY CHANGE Cumulative Incidence All other patients (n=254) 1 lesion 2-3 cm, complete 1 st treatment response, AFP < 20 (n= 63) Single Small Lesion Criteria Candidates who initially present w/ single 2-3 cm lesion must be treated with local-regional therapy (LRT) in order to be eligible for automatic MELD exception If the lesion is completely treated after 1+ LRTs, the candidate is not eligible for MELD exception until lesion recurs or develops a new lesion Months after listing If the lesion persists or recurs after 1+ LRTs, the candidate is eligible for MELD exception Mehta N, et al. Liver Transpl 2013;19:
7 OPTIMIZING SELECTION CRITERIA OPTIMIZING SELECTION CRITERIA Scenario: Your patient with a 3.5 cm HCC is at the top of the wait list and is expecting a liver offer at any time. Today in clinic he asks you what his expected outcomes are after transplant. Scenario: Your patient with a 3.5 cm HCC is at the top of the wait list and is expecting a liver offer at any time. Today in clinic he asks you what his expected outcomes are after transplant. 5 yr post-lt survival: yr HCC recurrence: ~15 OPTIMIZING SELECTION CRITERIA Scenario: Your patient with a 3.5 cm HCC is at the top of the wait list and is expecting a liver offer at any time. Today in clinic he asks you what his expected outcomes are after transplant. Do poorly after transplant?? Do poorly after transplant 5 yr post-lt survival:??? 5 yr HCC recurrence:??? 7
8 OPTIMIZING SELECTION CRITERIA OPTIMIZING SELECTION CRITERIA AFP Response to LRT Response to LRT 3.5 cm 3.5 cm OPTIMIZING SELECTION CRITERIA OPTIMIZING SELECTION CRITERIA AFP AFP Response to LRT 7.5 cm Response to LRT 7.5 cm 3.5 cm 3.5 cm 5 yr post-lt survival: 5 yr HCC recurrence: 8
9 DOWNSTAGING 7.5 cm DOWN-STAGING Down-staging: Reduction in the size of tumor(s) using LRT to meet acceptable LT criteria Tumor response to down-staging treatment is based on radiographic measurement of the size of viable tumors 3.5 cm 5 yr post-lt survival: 5 yr HCC recurrence: Yao FY, et al, Liver Transpl 2011; Ravaioli et al. Am J Transpl 2008; Pomfret et al. Liver Transplant 2010; Bruix, J et al EASL Practice Guidelines, J Hepatology 2012 UCSF DOWN-STAGING PROTOCOL Inclusion criteria - 1 lesion > 5 cm and 8 cm - 2 or 3 lesions 5 cm w/ total tumor diameter 8 cm - 4 or 5 lesions 3 cm w/ total tumor diameter 8 cm - No vascular invasion on imaging Candidates can undergo deceased-donor LT 3 months after down-staging if within Milan criteria Candidates can undergo LDLT 3 months after down-staging if within UCSF criteria* *1 lesion <6.5cm or 2-3 lesions <4.5cm with total tumor diameter <8cm Yao et al. Hepatology 2008;48: UCSF DOWN-STAGING 122 consecutive patients with HCC treated under UCSF down-staging protocol from Endpoint of down-staging: Residual tumor(s) within Milan criteria Down-staging group compared w/ 488 consecutive patients with initial HCC meeting T2 criteria listed for LT over same time period Median time from 1 st down-staging to LT 10 months Yao et al. Hepatology 2015;
10 Patient Proportion Survival without death POST-TRANSPLANT SURVIVAL Control down-staging Kaplan-Meier plot of Time to death By group P=0.87 Milan (T2) group (n= 332) Down-staging group (n= 68) Cont r ol : Median post-transplant follow-up 4.0 yrs 25 Down- st agi ng: Years Years from after the date Liver of Transplant liver transplant Log-Rank 228 Test P-Value is Proportion without recurrence Recurrence-free probability RECURRENCE-FREE PROBABILITY Control down-staging Kaplan-Meier plot of Time to recurrence By group Down-staging group (n= 68) P=0.31 Cont r ol : Down- st agi ng: Years Years from after the date Liver of Transplant liver transplant Milan (T2) group (n= 332) Log-Rank 213 Test P-Value is MULTI-CENTER DOWN-STAGING The UCSF down-staging protocol has been adopted by the rest of Region 5 Were our single center findings reproducible? REGION 5 DOWN-STAGING RESULTS 187 patients at UCSF, CPMC, and Scripps Successful down-staging: residual tumor(s) within Milan criteria 58 underwent LT a median of 13 months from 1 st down-staging procedure Favorable explant characteristics 81 within Milan 6 microvascular invasion 1 poorly differentiated tumor grade Mehta N et al. Hepatology 2014; 60 (Suppl):253A (AASLD 2014) 10
11 POST-TRANSPLANT SURVIVAL RECURRENCE-FREE PROBABILITY Probability of Survival Median post-lt follow-up period 4 years Recurrence Free Probability Years Post-Transplant Years Post-Transplant Mehta et al. AASLD 2014 PROPOSED UNOS POLICY CHANGES Downstaging Candidates that meet the UCSF/Region 5 downstaging protocol and then complete LRT must be successfully down-staged into Milan criteria to receive a MELD exception AFP AFP 3.5 cm 5 yr post-lt survival: 5 yr HCC recurrence: 11
12 AFP and Post-transplant Outcome- France AFP and Post-transplant Outcome - UCSF 100 Survival rate () P < n=387 n=109 n=61 AFP <100 AFP AFP >1000 AFP <1000 AFP >1000 p = Months after Liver Transplantation y Duvoux et al. Gastroenterology 2012;143: Hameed B. et al. Liver Transplantation 2014; AFP AND POST-LT HCC SURVIVAL UNOS Database from (n=45,267) AFP AND POST-LT HCC SURVIVAL UNOS Database from (n=45,267) Berry et al. Liver Transplantation 2013; Berry et al. Liver Transplantation 2013;
13 PROPOSED UNOS POLICY CHANGES High AFP Threshold Candidates with lesions meeting T2 criteria but with an AFP >1000 are not eligible for a standardized MELD exception If these lesions fall <500 after LRT, the candidate is eligible for a standardized MELD exception Candidates with an AFP level 500 at any time point following LRT will be referred to the review board OPTIMIZING SELECTION CRITERIA Response to LRT 3.5 cm 5 yr post-lt survival: 5 yr HCC recurrence: RESPONSE TO LOCAL-REGIONAL THERAPY AS PROGNOSTIC FACTOR Recurrence Rate () 18 5 Recurrence Free Survival () Risk factors - Radiologic tumor progression - AFP slope > 15 ng/ml/month, no risk factors Beyond Milan, no risk factors, (+) risk factors Beyond Milan, (+) risk factors Months after liver transplantation Kim DJ, et al. Am J Transpl 2014; Lai Q, et al. Liver Transpl 2013;19:
14 Recurrence Free Survival () 90 Risk factors - Radiologic tumor progression - AFP slope > 15 ng/ml/month, no risk factors Beyond Milan, no risk factors, (+) risk factors Beyond Milan, (+) risk factors Recurrence Free Survival () Risk factors - Radiologic tumor progression - AFP slope > 15 ng/ml/month, no risk factors Beyond Milan, no risk factors, (+) risk factors Beyond Milan, (+) risk factors Months after liver transplantation Months after liver transplantation Lai Q, et al. Liver Transpl 2013;19: Lai Q, et al. Liver Transpl 2013;19: OVERVIEW Current state of liver transplantation (LT) for HCC Let s push past the Milan criteria Refining selection criteria for LT Updates in down-staging outcomes Proposed UNOS policy changes DEVELOPMENT AND VALIDATION COHORTS Development cohort: 721 consecutive adult patients with HCC within Milan criteria who underwent LT from (UCSF, Mayo Roch, Mayo Jax) Validation cohort: 340 patients who underwent LT with same inclusion criteria at University of Toronto Risk factors for post-lt HCC recurrence How often to perform surveillance? 14
15 RECURRENCE RISK SCORE RETREAT Risk Estimation of Tumor REcurrence After Transplant RETREAT SCORE Predictor Points AFP at LT > Micro-vascular Invasion Yes 2 Largest Viable Tumor Size (cm) + Number of Viable Lesions >10 3 No RETREAT points scored for: AFP 0-20, no microvascular invasion, and explant pathology stage score of 0 RETREAT SCORE: 1 YR RECURRENCE Risk Estimation of Tumor REcurrence After Transplant (1 year) 1.0 C Concordance Statistic >5 _ RETREAT Score N= RETREAT SCORE: 5 YR RECURRENCE Risk Estimation of Tumor REcurrence After Transplant (5 years) C Concordance Statistic >5 _ RETREAT Score N=
16 VALIDATION OF RETREAT SCORE RETREAT score predicted recurrence in validation cohort better than Milan: RETREAT C index of 0.82 (95 CI ) Milan C index of 0.70 (95 CI ) USING RETREAT FOR HCC SURVEILLANCE AT UCSF RETREAT Proposed surveillance regimen 0 No surveillance (20 of the cohort) USING RETREAT FOR HCC SURVEILLANCE AT UCSF RETREAT Proposed surveillance regimen 0 No surveillance (20 of the cohort) 1-3 HCC surveillance every 6 months for 2 years 4 HCC surveillance every 6 months for 5 years USING RETREAT FOR HCC SURVEILLANCE AT UCSF RETREAT Proposed surveillance regimen 0 No surveillance (20 of the cohort) 1-3 HCC surveillance every 6 months for 2 years 4 HCC surveillance every 6 months for 5 years 5+ HCC surveillance every 3 months for 2 years; then every 6 months for years
17 USING RETREAT FOR HCC SURVEILLANCE AT UCSF RETREAT Proposed surveillance regimen 0 No surveillance (20 of the cohort) 1-3 HCC surveillance every 6 months for 2 years 4 HCC surveillance every 6 months for 5 years 5+ HCC surveillance every 3 months for 2 years; then every 6 months for years 2-5 Do poorly after transplant?? Do poorly after transplant Surveillance should be performed w/ multiphasic abdominal CT or MRI, chest CT, and AFP at the recommended interval. Do poorly after transplant?? ) High AFP 2) Poor response to LRT Do poorly after transplant 20 (or less urgent)?? 17
18 1) Single 2-3 cm lesion 2) Complete response to LRT 3) AFP <20 : IS THERE A PLACE FOR DOWN-STAGING? 20 Successful Down-staging (or less urgent)?? UCSF Transplant 2016: Building Bridges to Excellence THANKS! Special thanks to Dr. Francis Yao Questions? Neil.mehta@ucsf.edu 18
Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationHepatocellular Carcinoma: What the hepatologist wants to know
Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationHEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION. Francis Yao, M.D.
UCSF TRANSPLANT CONFERENCE - 9/28/2012 HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationHepatocellular Carcinoma Treatment Decision Tree
Treatment Decision Tree Derek DuBay, MD Assistant Professor of Surgery Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery 1 UAB Liver Tumor Clinic Referrals: 205 996 5970 (phone) 205
More informationHepatocellular Carcinoma Management Guidelines
Hepatocellular Carcinoma Management Guidelines By Ashraf Omar M.D, Prof. of Hepatology & Tropical Medicine Cairo University Staging Strategy and Treatment for Patients With HCC HCC PST 0, Child-Pugh A
More informationLiver Transplantation in Patients with Hepatocellular Carcinoma Across Milan Criteria
LIVER TRANSPLANTATION 14:272-278, 2008 ORIGINAL ARTICLE Liver Transplantation in Patients with Hepatocellular Carcinoma Across Milan Criteria J. Ignacio Herrero, 1 Bruno Sangro, 1 Fernando Pardo, 2 Jorge
More informationOptimal imaging surveillance schedules after liver directed therapy for hepatocellular carcinoma
Optimal imaging surveillance schedules after liver directed therapy for hepatocellular carcinoma F. Edward Boas, MD, PhD; Bao Do, MD; John D. Louie, MD; Nishita Kothary, MD; Gloria L. Hwang, MD; William
More informationHepatocellular carcinoma: A comprehensive review
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4254/wjh.v7.i26.2648 World J Hepatol 2015 November 18; 7(26): 2648-2663 ISSN 1948-5182 (online)
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Measure #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL HEPATOCELLULAR CARCINOMA GI Site Group Hepatocellular Carcinoma Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION
More informationManagement of Patients with Recurrent Hepatocellular Carcinoma Following Living Donor Liver Transplantation: A Single Center Experience
Management of Patients with Recurrent Hepatocellular Carcinoma Following Living Donor Liver Transplantation: A Single Center Experience Y. Gunay, N. Guler, M. Akyildiz, O. Yaprak, M. Dayangac, Y. Yuzer,
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationLiver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions
390 ORIGINAL ARTICLE October-December, Vol. 9 No.4, 2010: 390-396 Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions Timothy M. Schmitt,*
More informationCase Study in the Management of Patients with Hepatocellular Carcinoma
Management of Patients with Viral Hepatitis, Paris, 2004 Case Study in the Management of Patients with Hepatocellular Carcinoma Eugene R. Schiff This 50-year-old married man with three children has a history
More informationA New Priority Policy for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation Within the Model for End-Stage Liver Disease System
LIVER TRANSPLANTATION 13:857-866, 2007 ORIGINAL ARTICLE A New Priority Policy for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation Within the Model for End-Stage Liver Disease System
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More information*6816* 6816 CONSENT FOR DECEASED KIDNEY DONOR ORGAN OPTIONS
The shortage of kidney donors and the ever-increasing waiting list has prompted the transplant community to look at different types of organ donors to meet the needs of our patients on the waiting list.
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationAASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma Jordi Bruix 1 and Morris Sherman 2 Preamble These recommendations provide a data-supported approach to the diagnosis, staging and treatment
More informationMoving Beyond RECIST
Moving Beyond RECIST Ihab R. Kamel, M.D., Ph.D. ikamel@jhmi.edu Associate Professor Clinical Director, MRI Department of Radiology The Johns Hopkins University School of Medicine Outline Standard measures
More informationOPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors June 25-26, 2012 Richmond, VA.
OPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors June 25-26, 2012 Richmond, VA Summary I. Action Items for Board Consideration The Board is asked to approve
More informationTHE SECOND VERSION of Evidence-based Clinical
bs_bs_banner doi: 10.1111/hepr.12464 Special Report Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) Norihiro
More informationLocoregional Treatment of Hepatocellular Carcinoma. Cory Johnston and Sung Cho HPB Surgery Fellows Providence Portland, Oregon
Locoregional Treatment of Hepatocellular Carcinoma Cory Johnston and Sung Cho HPB Surgery Fellows Providence Portland, Oregon Hepatocellular Carcinoma The 3 rd most common cause of cancer- related death
More informationHepatocellular Carcinoma: A Guide to Screening and Diagnosis
February 2012 Hepatocellular Carcinoma: A Guide to Screening and Diagnosis Reid Merryman, Harvard Medical School Year III Agenda Hepatocellular carcinoma (HCC) introduction Index patient: clinical presentation
More informationNew Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma. Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma
New Data Supporting Modified RECIST (mrecist) for Hepatocellular Carcinoma Running Title: Modified RECIST (mrecist) for Hepatocellular Carcinoma Riccardo Lencioni Author s Affiliation: Division of Diagnostic
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationHepatocellular carcinoma: Algorithms of diagnosis and options of therapy
Hepatocellular carcinoma: Algorithms of diagnosis and options of therapy Alejandro Forner BCLC Group. Liver Unit. Hospital Clinic. University of Barcelona Pathogenesis and Clinical Practice in Gastroenterology
More informationClinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations. Chapter. Grade. CQ No. 1 Interferon Therapy
Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations Chapter Chapter 1 Prevention Sectio n CQ No. 1 Interferon Therapy Clinical Question 1 Does interferon
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationLIVER TRANSPLANTATION IN ALAGILLE SYNDROME
LIVER TRANSPLANTATION IN ALAGILLE SYNDROME Ronald J. Sokol, MD Children s Hospital Colorado University of Colorado School of Medicine Treatment of Liver Disease in Improve bile flow ALGS Ursodeoxycholic
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationEvaluation and Prognosis of Patients with Cirrhosis
Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationLeading the Way to Treat Liver Cancer
Leading the Way to Treat Liver Cancer Guest Expert: Sukru, MD Professor of Transplant Surgery Mario Strazzabosco, MD Professor of Internal Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale
More informationHepatocellular Carcinoma (HCC)
Abhishek Vadalia Introduction Chemoembolization is being used with increasing frequency in the treatment of solid hepatic tumors such as Hepatocellular Carinoma (HCC) & rare Cholangiocellular Carcinoma
More informationUpdate on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationNOVEL PLATFORMS FOR CANCER DIAGNOSIS
NOVEL PLATFORMS FOR CANCER DIAGNOSIS Luca Beneduce, Ph.D. Founded in 2001 and headquartered in Venice (Italy) Xeptagen is a privately held biotech company funded by venture capital. Xeptagen s mission
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationUse of Nucleic Acid Amplification Tests in TB patients in California 2010-2012
Use of Nucleic Acid Amplification Tests in TB patients in California 2010-2012 Lisa Pascopella, PhD, MPH Pennan Barry, MD, MPH Tuberculosis Control Branch, Division of Communicable Disease Control, Center
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationCLINICAL GUIDELINE FOR ADVANCED NURSE PRACTITIONER HEPATOLOGY (GASTROENTEROLOGY) 1. Aim/Purpose of this Guideline:
CLINICAL GUIDELINE FOR ADVANCED NURSE PRACTITIONER HEPATOLOGY (GASTROENTEROLOGY) 1. Aim/Purpose of this Guideline: 1.1. This protocol applies to Advanced Nurse Practitioners (Hepatology) employed by RCHT
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationEarly Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D.
Early Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D. Professor of Medicine Germanis Kaufman Chair of Gastroenterology Director, Dept. of Gastroenterology Chaim Sheba Medical Center,
More informationThe Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection
Yonsei Medical Journal Vol. 47, No. 1, pp. 105-112, 2006 The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative Resection Jae Gil Lee, 1,2 Chang Mu Kang, 1 Joon Seong Park,
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationDavid Axelrod, MD, MBA Associate Professor of Surgery Section Chief Solid Organ Transplantation Dartmouth Hitchcock Medical Center
David Axelrod, MD, MBA Associate Professor of Surgery Section Chief Solid Organ Transplantation Dartmouth Hitchcock Medical Center Economic analysis team Mark Schnitzler, Ph.D. Krista Lentine MD, Ph.D.
More informationBridging Techniques. What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS
Bridging Techniques What s between EMR and Traditional Surgery? Elisabeth C. McLemore, MD, FACS, FASCRS Associate Professor of Surgery Assistant Program Director, General Surgery Residency Disclosures
More informationHIV and Liver Transplantation: challenges and opportunities
HIV and Liver Transplantation: challenges and opportunities HIVPA Brighton June 2009 D Joshi Institute of Liver Studies King s College Hospital Key messages Identifying patients early Causes of liver disease
More informationTRANSPLANTATION HEPATIQUE POUR CARCINOME HEPATOCELLULAIRE
TRANSPLANTATION HEPATIQUE POUR CARCINOME HEPATOCELLULAIRE Professeur Didier SAMUEL Centre Hepatobiliaire, INSERM Unit 785 Hopital Paul Brousse, Université Paris Sud Guidelines de Prise en Charge du CHC
More informationBreast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies
Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microwave_tumor_ablation 12/2011 11/2015 11/2016 11/2015 Description of Procedure or Service Microwave ablation
More informationLIVER TUMORS PROFF. S.FLORET
LIVER TUMORS PROFF. S.FLORET NEOPLASM OF LIVER PRIMARY 1)BENIGN 2)MALIGNANT METASTATIC/SECONDARY LIVER Primary Liver Cancer the Second Killer among tumors high morbidity and mortality(20.40/100,000) etiology
More information4/25/2016. Transplant Journey. Objectives. Reason for Transplantation at Mayo Clinic. Mayo Clinic Model of Care
Transplant Journey Lynette Fix, RN, BAN, CCTC Objectives Identify key components of transplant evaluation process Identify the patient follow-up process Describe diseases indicated for transplantation
More informationNP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
More informationAppendix G - Identification and Selection of Studies
FINAL Emergency framework for rationing of blood for massively bleeding patients during a red phase of a Appendix G - Identification and Selection of Studies Inclusion/Exclusion Criteria We included studies
More informationNew Kidney Allocation and What it Means to Your Transplant Center and Your Patients
New Kidney Allocation and What it Means to Your Transplant Center and Your Patients Alexander Wiseman, M.D. Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationFOLLOW UP OF TREATED NON-SMALL CELL LUNG CANCER PATIENTS
FOLLOW UP OF TREATED NON-SMALL CELL LUNG CANCER PATIENTS THE ART AND THE SCIENCE GIOVANNI BATTISTA MORGAGNI 1682-1771 ITALIAN ANATOMIST FATHER OF PATHOLOGIC ANATOMY 1 ST DESCRIPTION OF LUNG CANCER IN 1761
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationManagement of Hepatocellular
Clinician s Guide version 08-05-09 Management of Hepatocellular Carcinoma (HCC) U.S. Department of Veterans Affairs Veterans Health Administration VA Hepatitis C Resource Center Program & VA National Clinical
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationInnovative RT SBRT. The variables with REQ in superscript are required.
The variables with REQ in superscript are required. The variables with a are single-select variables; only one answer can be selected. The variables with a are multi-select variables; multiple answers
More informationPAH in. Registry to Evaluate Early and Long-Term PAH Disease Management
PAH in Registry to Evaluate Early and Long-Term PAH Disease Management Ioana R. Preston, MD Co-Director, Pulmonary Hypertension Center Tufts Medical Center, Boston, MA Background What is REVEAL? Multi-center,
More informationYttrium-90 Radioembolization
Yttrium-90 Radioembolization Yttrium-90 radioembolization is generally used as a palliative therapy for selected patients with unresectable tumors of the liver including: Metastatic tumors from colorectal
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationPredicting Prognosis in Hepatocellular Carcinoma: Comparison of Staging Systems in Pakistani Cohort
ORIGINAL ARTICLE Predicting Prognosis in Hepatocellular Carcinoma: Comparison of Staging Systems in Pakistani Cohort Shahid Sarwar 1, Anwaar A. Khan 1 and Shandana Tarique 2 ABSTRACT Objective: To determine
More informationQuestions and Answers for Transplant Candidates about the New Kidney Allocation System
TA L K I N G A B O U T T R A N S P L A N TAT I O N U N I T E D N E T W O R K F O R O R G A N S H A R I N G Questions and Answers for Transplant Candidates about the New Kidney Allocation System United
More informationSupplementary Online Content
Supplementary Online Content Harshman, LC, Wang X, Nakabayashi M, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive
More informationRacial and Insurance Disparities in the Receipt of Transplant Among Patients With Hepatocellular Carcinoma
Racial and Insurance Disparities in the Receipt of Transplant Among Patients With Hepatocellular Carcinoma Jeanette C. Yu, MD, MPH 1 ; Alfred I. Neugut, MD, PhD 1,2 ; Shuang Wang, PhD 3 ; Judith S. Jacobson,
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationLow-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
More informationIssues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
More informationBAISHIDENG PUBLISHING GROUP INC
Reviewer s code: 01714224 Reviewer s country: Italy Date reviewed: 2015-01-30 20:36 [ Y] Grade A: Priority publishing [ ] Accept [ ] Grade C: Good [ Y] Grade D: Fair language [ Y] Major revision The article
More informationTransplant Report. UMassMemorial Medical Center A Member of UMass Memorial Health Care
Transplant Report UMassMemorial Medical Center A Member of UMass Memorial Health Care A Message from the Chief Dear Colleague: In recent years, UMass Memorial Medical Center has made significant strides
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationSaturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies
Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies John F. Ward, MD Assistant Professor University of Texas M. D. Anderson Cancer Center Ablation
More informationThe New Kidney Allocation System: Resources for Protocols and Processes webinar.
The New Kidney Allocation System: Resources for Protocols and Processes webinar. 1 Speakers for the webinar are: Dr. Richard Formica Associate Professor of Medicine and Surgery, Yale University School
More informationYour Guide to Express Critical Illness Insurance Definitions
Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses
More informationImage. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
More informationUK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults
UK Guidelines for the management of suspected hepatocellular carcinoma (HCC) in adults SD Ryder DM FRCP Consultant Hepatologist Queens Medical Centre Nottingham University Hospitals NHS Trust Wolfson Digestive
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationThe State of the Liver in the Adult Patient after Fontan Palliation
The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital
More informationScreening for hepatocellular carcinoma: survival benefit and cost-effectiveness
Review Annals of Oncology 14: 1463 1467, 2003 DOI: 10.1093/annonc/mdg400 Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness M.-F. Yuen & C.-L. Lai* Department of Medicine,
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More information